To examine whether the enhanced ability of CD5-/- DC to promote CD4+ Th1 and CD8+ T cells leads to more robust anti-tumor immune responses, naϊve mice were immunized subcutaneously with WT or CD5-/- BMDC pulsed with OVA. The gene discussed is CD8A; the disease is neoplasm.